[Section 3.27(a)(i)] of the Disclosure Schedules sets forth a current, complete and accurate list of each Government Contract by contract number or other generalized reference in compliance with applicable security clearance protocols, including, for the avoidance of doubt, all purchase orders, task orders, and delivery orders the period of performance of which has not yet expired or been terminated or for which the final payment has not yet been received, or which remains subject to audit (collectively, the “Current Government Contracts”) the funded value, the total contract value or total estimated contract value (inclusive of options) and the period of performance (including all unexercised option periods). The Company has not received notice that any Current Government Contract is the subject of bid or award protest proceedings and, to Seller’s Knowledge, no such Current Government Contract is reasonably likely to become the subject of bid or award protest proceedings. The Company has delivered to Buyer complete and correct copies of each such Current Government Contract, including all material correspondence, modifications, statements of work purchase orders, task orders or delivery orders issued under such Current Government Contracts.

Notwithstanding [Section 3.1(a)] hereof and the Grant Notice, but subject to [Section 3.1(b)] hereof, in the event of a Change in Control the Option shall be treated pursuant to [Sections 9.2 and 9.3]3] of the Plan.

[Section 3.09(a)] of the Disclosure Schedules lists each of the following Contracts of the Company (including Contracts which are Transferred Assets) (such Contracts being “Material Contracts”):

Notwithstanding [Section 3.2(b)(i)], the option period for a Future Non-Oncology Invention shall expire # ​ after the Future Non-Oncology Invention Disclosure Date if such Future Non-Oncology Invention has not been incorporated into the Development Plan within such ​ period (provided that # the option period shall not so expire if such Future Non-Oncology Invention is not incorporated into the Development Plan due to Baylor’s JSC members not agreeing to incorporate such Future Non-Oncology Invention into the Development Plan or Baylor’s lack of resources CONFIDENTIAL

[Section 3.2.3(a)] (Co-Funded Expenses) of the Agreement is hereby deleted in its entirety and replaced with the following:

[Section 3.2.3(b)] (PMR/PMC Activities) of the Agreement is hereby deleted in its entirety and replaced with the following:

[Section 3.2.3(d)] (Reimbursement for Additional Studies) of the Agreement is hereby deleted in its entirety and replaced with the following:

Notwithstanding [Section 3.1(a)], the option period for a Future Oncology Invention shall expire # ​ after the Future Oncology Invention Disclosure Date if such Future Oncology Invention has not been incorporated into the Development Plan within such ​ period (provided that # the option period shall not so expire if such Future Oncology Invention is not incorporated into the Development Plan due to Baylor’s JSC members not agreeing to incorporate such Future Oncology Invention into the Development Plan or Baylor’s lack of resources or capacity to perform Early R&D Activities for such Future Oncology Invention, or # if any part of the FIM Study is conducted by Baylor, then such option shall not expire until ​ after the delivery to Cell Medica of the Data Package for such FIM Study with respect to such Future Oncology Invention; or # if such Future Oncology Invention is dropped from the Development Plan, twelve (12) months after such Future Oncology Invention is dropped from the Development Plan, provided that such Future Oncology Invention is not dropped from the Development Plan due to Baylor’s lack of resources or capacity to perform Early R&D Activities for such Future Oncology Invention​.

[Section 3.7] of the Agreement is hereby deleted and replaced with the following:

[Section 3.1.5] (Co-Funded Development Plan) of the Agreement is hereby deleted in its entirety and replaced with the following: